Medicine BPC-157

RESEARCH DIGEST * THE RECORD 06

Every BPC-157 source, pinned to the board.

The studies and FDA documents behind every number on this site, each with its PMID, DOI, or URL. Open them and check us.

Back to the researchRead the FAQ

BPC-157 research references

Every claim on this site maps to one of the entries below. The preclinical core runs from the foundational rat tendon and gastric-ulcer studies through the 2017 VEGFR2 angiogenesis mechanism and the 2022 pharmacokinetic characterization; the human record is the three small pilots; and the regulatory facts are drawn from the FDA's own compounding pages. Numbers in brackets throughout the site correspond to the numbered list rendered here. Nothing on this page is a recommendation to obtain or administer BPC-157 — it is a reading list for the research record, and it is sold by no one.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. ↗
  3. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. ↗
  4. Xue XC, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10(7):1032-1037. ↗
  5. Novinscak T, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2008;38(8):716-725. ↗
  6. Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. Biomedicines. 2022;10(12):3221. ↗
  7. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. ↗
  8. McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. (Human-data context throughout; concludes BPC-157 is investigational with only three small human pilots.) See also Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025 (PMID 40131143); and Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024 (PMID 39325560). ↗
  9. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Calendar. (Lists BPC-157, KPV, TB-500, and MOTs-C as bulk drug substances being considered for inclusion on the 503A Bulks List; a scheduled discussion, not a decision.) ↗
  10. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (Definitions of Category 1 and Category 2; the bulks-list and PCAC framework; the January 7, 2025 change to categorizing newly nominated substances.) ↗
  11. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. (Category 2 entries for 'BPC-157 (free base)' and 'BPC-157 acetate'; FDA's stated safety rationale; effective with the September 29, 2023 update.) ↗
  12. U.S. Food and Drug Administration. Human Drug Compounding — sections 503A and 503B framework and the lawful access pathway (licensed-prescriber evaluation, valid patient-specific prescription, 503A compounding pharmacy or 503B outsourcing facility; ingredient-eligibility requirement; telehealth as a front-end consultation channel only). ↗